Trial Profile
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adrenocortical carcinoma; Carcinoma; Cervical cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Neuroendocrine carcinoma; Ovarian cancer; Paraganglioma; Penile cancer; Phaeochromocytoma; Renal cell carcinoma; Sarcoma; Skin cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Testicular cancer; Thymoma; Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 18 May 2023 Planned End Date changed from 20 Dec 2022 to 31 Dec 2025.
- 18 May 2023 Planned primary completion date changed from 20 Dec 2022 to 31 Dec 2025.
- 20 Apr 2022 Planned End Date changed from 20 Dec 2021 to 20 Dec 2022.